Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Eleda in connection with the acquisition of Gatu och Väg Väst AB
Mandate

Vinge advises Eleda in connection with the acquisition of Gatu och Väg Väst AB

January 15, 2021 Employment and Benefits EU, Competition and Regulatory Real Estate and Construction M&A Corporate Crime & Compliance

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Gatu och Väg Väst AB (“GVV”).

GVV is based in Gunnilse and conducts construction and contracting operations in the south western Sweden, focusing on concrete maintenance work on, inter alia, bridges, power plants and port facilities. GVV has approximately 70 employees and yearly sales of around SEK 240 million. The company’s management team will continue in their respective operational management roles and become shareholders of the Eleda group.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted primarily of partner Christina Kokko and associates Michaela Cronemyr and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Agreements), Ebba Svenburg (Employment), Frida Ställborn (Real Property & Environment), Johan Wahlbom and Joel Kokko (Competition), Tove Lövgren Frisk (Compliance) and Carl Bruneheim (VDR-specialist).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026